Friday 6 November 2026
Export TRLV’s income statement to Excel — free account
Trulieve Cannabis Corp.
TRLV Healthcare Drug Manufacturers Specialty & Generic
Trulieve Cannabis Corp.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- −20.1%
- EPS
- −2,391.1%
- Free cash flow
- +24.5%
- Total debt
- −37.0%
Quarter to September 2026, against a year earlier
11.54
0.64
+5.87%
Follow TRLV
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 5 | 6 |
+8 more TTM periods Free account |
| (45.52%) | (47.92%) | (6.85%) | (9.73%) | ||
| (17.61%) | (18.93%) | (2.86%) | (4.18%) | ||
ROIC |
0.00% | (21.87%) | 7.77% | 7.61% | |
Return on Tangible Assets |
(42.29%) | (44.92%) | (6.73%) | (10.52%) | |
Average Days of Receivables |
0.00 | 8.66 | 6.49 | 5.86 | |
Free Cash Flow per Share |
1.26 | 0.97 | 1.16 | 1.11 | |
Free Cash Flow |
242.48 | 186.25 | 224.20 | 212.31 | |
Capital Expenditures |
— | (58.20) | (53.20) | (60.51) | |
| Other line items | |||||
Cash ROIC |
31.43% | 12.97% | 12.04% | 12.56% | |
Accounts Receivable Turnover |
0.00 | 50.51 | 58.96 | 63.42 | |
Accounts Payable Turnover |
5.69 | 6.57 | 5.55 | 5.32 | |
Inventory Turnover |
1.96 | 2.16 | 1.96 | 1.98 | |
Average Days of Payables |
58.49 | 48.62 | 61.02 | 64.19 | |
Days of Inventory on Hand |
163.69 | 147.75 | 187.33 | 188.16 | |
Tax Rate |
0.36 | 0.44 | (1.84) | (2.28) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
38.93% | 37.93% | 36.86% | 37.69% | |
Share Based Compensation of Revenue |
1.94% | 1.83% | 1.77% | 1.73% | |
Interest Coverage |
0.00 | (4.84) | 2.38 | 2.26 | |
Operating CF/Net income |
(0.54) | (0.52) | (3.42) | (2.34) | |
Depreciation/Fixed assets |
0.00 | 0.29 | 0.26 | 0.26 | |
Capex/Depreciation |
— | (0.34) | (0.31) | (0.35) | |
Revenue per Share |
5.60 | 5.91 | 6.08 | 6.17 | |
Operating CF per Share |
1.26 | 1.27 | 1.44 | 1.43 | |
Capex per Share |
0.00 | (0.30) | (0.28) | (0.32) | |
Capex to Sales |
0.00 | 0.05 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026